Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 131

Sort by

Sort Order Select

Journal Articles

RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-142514

Published: 2020

Journal Articles

TRAF2 Mediates Sensitivity to Immunomodulatory Drugs in the Bone Marrow Microenvironment

Jiye Liu, PhD, Teru Hideshima, MD PhD, Lijie Xing, MD, Su Wang, PhD, Daisuke Ogiya, MD PhD, Mehmet K. Samur, PhD, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth Wen, Yu-Tzu Tai, PhD, Yong Cang, PhD, Kenneth Anderson, MD

Blood (2020) 136 (Supplement 1): 31.

https://doi.org/10.1182/blood-2020-139778

Published: 2020

Journal Articles

Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated By Cgas/Sting Pathway Activation, Type I Interferon Secretion, and Immunogenic Cell Death: Clinical Application

Annamaria Gulla, MD, Eugenio Morelli, MD, Mehmet Kemal Samur, PhD, Cirino Botta, MDPhD, Teru Hideshima, MD PhD, Giada Bianchi, MD, Mariateresa Fulciniti, PhD, Stefano Malvestiti, MD, Rao Prabhala, Srikanth Talluri, PhD, Yu-Tzu Tai, PhD, Kenneth Wen, Paul G. Richardson, MD, Ruben D. Carrasco, MD PhD, Dharminder Chauhan, PhD, Nikhil C. Munshi, MD, Kenneth Anderson, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-140356

Published: 2020

Journal Articles

Aberrant RHAMM Splicing in Multiple Myeloma (MM) and Its Implications for Immunotherapy

Daisuke Ogiya, MD PhD, Lisa Müller, Sigitas J Verselis, PhD, Heiner Schaal, PhD, Ivane Abiatari, MD, Ana M Stenstrom, Catherine A Nicholas, John F Daley, Michael P. Chu, David M. Dorfman, MD PhD, Linda M. Pilarski, PhD, Teru Hideshima, MD PhD, Kenneth C. Anderson, MD, Sophia Adamia, PhD

Blood (2019) 134 (Supplement_1): 1804.

https://doi.org/10.1182/blood-2019-131775

Published: 2019

Journal Articles

TNF-α Confers Resistance of Myeloma Cells to IMiDs through TRAF2 Degradation

Jiye Liu, PhD, Teru Hideshima, MD PhD, Lijie Xing, MD, Kenneth Wen, BS, Yu-Tzu Tai, PhD, Yong Cang, PhD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 1809.

https://doi.org/10.1182/blood-2019-123141

Published: 2019

Journal Articles

Altered Genomic and Epigenetic Profiling of Myeloma Bone Marrow Stromal Cells Identifies Targets for Current and Future Immunotherapeutic Approaches

Sophia Adamia, PhD, Daisuke Ogiya, MD PhD, Ivane Abiatari, MD, Sigitas J Verselis, PhD, Michael P. Chu, David M. Dorfman, MD PhD, Linda M. Pilarski, PhD, Teru Hideshima, MD PhD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 3079.

https://doi.org/10.1182/blood-2019-131243

Published: 2019

Journal Articles

Loss-of-Function of Gabarap Impairs Bortezomib-Induced Anti-Tumor Immunity in Multiple Myeloma: Clinical Application

Annamaria Gulla, MD, Eugenio Morelli, MD, Mehmet Kemal Samur, PhD, Teru Hideshima, MD PhD, Giada Bianchi, MD, Mariateresa Fulciniti, PhD, Rao Prabhala, Srikanth Talluri, PhD, Yu-Tzu Tai, PhD, Dharminder Chauhan, PhD, Ruben D. Carrasco, MD PhD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 134.

https://doi.org/10.1182/blood-2019-127845

Published: 2019

Journal Articles

Myeloma Heterogeneity within Its Complex Immune Ecosystem

Jana Jakubikova, PhD, Danka Cholujova, PhD, Gabor Beke, PhD, Zachary R Hunter, PhD, Teru Hideshima, MD PhD, Merav Leiba, MD, Krzysztof Jamroziak, MD PhD, Paul G. Richardson, MD, Eftathios Kastritis, David M. Dorfman, MD PhD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 4354.

https://doi.org/10.1182/blood-2019-132193

Published: 2019

Journal Articles

High-Dimensional Heterogeneity of Waldenström Macroglobulinemia within Its Immune Tumor Microenvironment

Jana Jakubikova, PhD, Danka Cholujova, PhD, Gabor Beke, PhD, Zachary R Hunter, PhD, Teru Hideshima, MD PhD, Ludmila Flores, Merav Leiba, MD, Paul G. Richardson, MD, Eftathios Kastritis, David M. Dorfman, MD PhD, Steven P Treon, MD PhD FRCP, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 3975.

https://doi.org/10.1182/blood-2019-130011

Published: 2019

Journal Articles

Development TACI and Bcma Dual-Antigen Targeted Immunotherapy for Multiple Myeloma

Jooeun Bae, PhD, Teru Hideshima, MD PhD, Mehmet Kemal Samur, PhD, Paul G. Richardson, MD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 3138.

https://doi.org/10.1182/blood-2019-128689

Published: 2019

Journal Articles

Novel Therapeutic Rationale for Targeting HDAC1 and PIM2 in Multiple Myeloma

Takeshi Harada, MD PhD, Asuka Oda, Hiroto Ohguchi, MD PhD, Yohann Grondin, PhD, Hirofumi Tenshin, DDS, PhD, Masahiro Hiasa, DDS, PhD, Jumpei Teramachi, Masahiro Oura, MD, Kimiko Sogabe, MD, Shiro Fujii, MD PhD, Shingen Nakamura, MD PhD, Hirokazu Miki, MD PhD, Kumiko Kagawa, MD PhD, Shuji Ozaki, MD PhD, Teru Hideshima, MD PhD, Kenneth C. Anderson, MD, Masahiro Abe, MD PhD

Blood (2019) 134 (Supplement_1): 3111.

https://doi.org/10.1182/blood-2019-127679

Published: 2019

Journal Articles

Cell Type-Specific Deregulation of Polypyrimidine Tract- Binding Proteins (PTBPs) Drive Aberrant Splicing in Multiple Myeloma (MM) and Acute Myeloid Leukemia (AML)

Sophia Adamia, PhD, Sigitas J Verselis, PhD, Teru Hideshima, MD PhD, Michael P. Chu, MD, Shruti Bhatt, PhD, David P. Steensma, MD, Daniel J Deangelo, Richard M. Stone, MD, Daniel G. Tenen, MD, Linda M. Pilarski, PhD, James D. Griffin, MD, Kenneth Anderson, MD

Blood (2018) 132 (Supplement 1): 3895.

https://doi.org/10.1182/blood-2018-99-118501

Published: 2018

Journal Articles

Genome-Wide CRISPR-Cas9 Screening Reveals a Role for TRAF2 in Resistance to IMiDs in Multiple Myeloma

Jiye Liu, PhD, Wenrong Zhou, PhD, Lijie Xing, MD, Liang Lin, PhD, Kenneth Wen, BS, Yu-Tzu Tai, PhD, Teru Hideshima, MD PhD, Yong Cang, PhD, Kenneth C. Anderson, MD

Blood (2018) 132 (Supplement 1): 1917.

https://doi.org/10.1182/blood-2018-99-111962

Published: 2018

Journal Articles

Optimizing Mechanisms for Induction of Immunogenic Cell Death to Improve Patient Outcome in Multiple Myeloma

Annamaria Gulla, MD, Eugenio Morelli, MD, Teru Hideshima, MD PhD, Mehmet Kemal Samur, PhD, Giada Bianchi, MD, Mariateresa Fulciniti, PhD, Nikhil Munshi, MD, Kenneth C. Anderson, MD

Blood (2018) 132 (Supplement 1): 1932.

https://doi.org/10.1182/blood-2018-99-116951

Published: 2018

Journal Articles

JAK-STAT3 Pathway Regulates CD38 Expression on Multiple Myeloma Cells

Daisuke Ogiya, MD PhD, Jiye Liu, PhD, Hiroto Ohguchi, MD PhD, Yu-Tzu Tai, PhD, Teru Hideshima, MD PhD, Kenneth Anderson, MD

Blood (2018) 132 (Supplement 1): 4440.

https://doi.org/10.1182/blood-2018-99-112425

Published: 2018

Journal Articles

The Critical Role of HDAC1-IRF4-Pim-2 Axis in Myeloma Cell Growth and Survival: Therapeutic Impacts of Targeting the HDAC1-IRF4-Pim-2 Axis

Takeshi Harada, MD PhD, Asuka Oda, PhD, Yohann Grondin, PhD, Jumpei Teramachi, DDS, PhD, Ariunzaya Bat-Erdene, MD PhD, Masami Iwasa, MD, Masahiro Oura, MD, Shingen Nakamura, MD PhD, Kumiko Kagawa, MD PhD, Yasunobu Okamoto, MD, Kimiko Sogabe, MD, Shiro Fujii, MD, Hirokazu Miki, MD PhD, Shuji Ozaki, MD PhD, Teru Hideshima, MD PhD, Kenneth C. Anderson, MD, Masahiro Abe, MD PhD

Blood (2018) 132 (Supplement 1): 1939.

https://doi.org/10.1182/blood-2018-99-114086

Published: 2018

Journal Articles

Selective Targeting of Multiple Myeloma By Bcma-Specific Central Memory CD8 + cytotoxic T Lymphocytes: A Potential Immunotherapeutic Application in Multiple Myeloma and Other Plasma Cell Disorders

Jooeun Bae, PhD, Teru Hideshima, MD PhD, Nikhil Munshi, MD, Kenneth C. Anderson, MD

Blood (2018) 132 (Supplement 1): 3196.

https://doi.org/10.1182/blood-2018-99-117282

Published: 2018

Journal Articles

Novel Mechanisms Underlying IMiDs Resistance in Multiple Myeloma: Therapeutic Implications

Jiye Liu, PhD, Wenrong Zhou, PhD, Lijie Xing, MD, Matthew Ho, Kenneth Wen, BS, Tianyu Song, Yu-Tzu Tai, PhD, Teru Hideshima, MD PhD, Yong Cang, PhD, Kenneth C Anderson, MD

Blood (2017) 130 (Supplement 1): 594.

https://doi.org/10.1182/blood.V130.Suppl_1.594.594

Published: 2017

Journal Articles

Pembrolizumab (anti-PD-1) Treatment Increases Anti-Tumor Activities of XBP1/CD138/CS1-Specific Cytotoxic T Lymphocytes Against Multiple Myeloma

Jooeun Bae, PhD, Derin Keskin, PhD, Yu-Tzu Tai, PhD, Teru Hideshima, MD PhD, Nikhil Munshi, MD, Kenneth C Anderson, MD

Blood (2017) 130 (Supplement 1): 1867.

https://doi.org/10.1182/blood.V130.Suppl_1.1867.1867

Published: 2017

Journal Articles

Immunomodulatory Effects of HDACi in Combination with Checkpoint Blockade and Lenalidomide in the Immunosuppressive Multiple Myeloma Bone Marrow Microenvironment

Greg D Whitehill, BS, Alicia Chivers, MS, Bryan Danielson, PhD, Julien SR Tessier, MS, Gabriela Hernandez Duran, Gabrielle L Bender, BS, Douglas W. Sborov, MD MSc, Craig C Hofmeister, MDMPH, James Bradner, MD, Teru Hideshima, MD PhD, Kenneth C Anderson, MD, Gullu Gorgun, PhD

Blood (2017) 130 (Supplement 1): 4422.

https://doi.org/10.1182/blood.V130.Suppl_1.4422.4422

Published: 2017

NARROW

RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma

TRAF2 Mediates Sensitivity to Immunomodulatory Drugs in the Bone Marrow Microenvironment

Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated By Cgas/Sting Pathway Activation, Type I Interferon Secretion, and Immunogenic Cell Death: Clinical Application

Aberrant RHAMM Splicing in Multiple Myeloma (MM) and Its Implications for Immunotherapy

TNF-α Confers Resistance of Myeloma Cells to IMiDs through TRAF2 Degradation

Altered Genomic and Epigenetic Profiling of Myeloma Bone Marrow Stromal Cells Identifies Targets for Current and Future Immunotherapeutic Approaches

Loss-of-Function of Gabarap Impairs Bortezomib-Induced Anti-Tumor Immunity in Multiple Myeloma: Clinical Application

Myeloma Heterogeneity within Its Complex Immune Ecosystem

High-Dimensional Heterogeneity of Waldenström Macroglobulinemia within Its Immune Tumor Microenvironment

Development TACI and Bcma Dual-Antigen Targeted Immunotherapy for Multiple Myeloma

Novel Therapeutic Rationale for Targeting HDAC1 and PIM2 in Multiple Myeloma

Cell Type-Specific Deregulation of Polypyrimidine Tract- Binding Proteins (PTBPs) Drive Aberrant Splicing in Multiple Myeloma (MM) and Acute Myeloid Leukemia (AML)

Genome-Wide CRISPR-Cas9 Screening Reveals a Role for TRAF2 in Resistance to IMiDs in Multiple Myeloma

Optimizing Mechanisms for Induction of Immunogenic Cell Death to Improve Patient Outcome in Multiple Myeloma

JAK-STAT3 Pathway Regulates CD38 Expression on Multiple Myeloma Cells

The Critical Role of HDAC1-IRF4-Pim-2 Axis in Myeloma Cell Growth and Survival: Therapeutic Impacts of Targeting the HDAC1-IRF4-Pim-2 Axis

Selective Targeting of Multiple Myeloma By Bcma-Specific Central Memory CD8 + cytotoxic T Lymphocytes: A Potential Immunotherapeutic Application in Multiple Myeloma and Other Plasma Cell Disorders

Novel Mechanisms Underlying IMiDs Resistance in Multiple Myeloma: Therapeutic Implications

Pembrolizumab (anti-PD-1) Treatment Increases Anti-Tumor Activities of XBP1/CD138/CS1-Specific Cytotoxic T Lymphocytes Against Multiple Myeloma

Immunomodulatory Effects of HDACi in Combination with Checkpoint Blockade and Lenalidomide in the Immunosuppressive Multiple Myeloma Bone Marrow Microenvironment

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only